🇺🇸 Tenofovir, Emtricitabine, Raltegravir in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 2
Most-reported reactions
- Drug Effect Incomplete — 1 report (50%)
- Pulmonary Tuberculosis — 1 report (50%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is Tenofovir, Emtricitabine, Raltegravir approved in United States?
Tenofovir, Emtricitabine, Raltegravir does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Tenofovir, Emtricitabine, Raltegravir in United States?
Hospital Clinic of Barcelona is the originator. The local marketing authorisation holder may differ — check the official source linked above.